Skip to main content
OpenTrials
Completed

NCT Number: NCT05162248

Microsatellite Instability in Colorectal Cancers

In this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) in patients who underwent surgery for colorectal cancer. We also planned to determine how MSI affects prognostic parameters.

Completed

Looking for future studies?

Notify Me

Key information

About this study

According to Global Cancer Statistics, higher than 1.9 million new cases of colorectal cancer (CRC) and 935,000 deaths are estimated to occur in 2020, representing about one in 10 cancer cases and deaths. Overall, it ranks third in colorectal incidence but second in mortality.

In CRC evolution, the acquisition of genomic instability is a critical point, and there are at least two different pathways in the pathogenesis of CRC: the chromosomal instability (CIN) pathway (85%) and the microsatellite instability (MSI) pathway (15%).

Microsatellite instability (MSI) is a phenotype that occurs due to a malfunction in the DNA repair mechanism and is seen in approximately 15% of colorectal cancers (CRCs). CRCs with MSI have different clinical features, such as a tendency to settle in the proximal colon, poor differentiation, and more lymphocytic infiltration in the tumor. It has been shown that CRCs with MSI have a better prognosis and respond differently to chemotherapy than CRCs with microsatellite stable (MSS).

We aimed to evaluate the different histopathological features of tumors with MSI compared to MSS in patients who underwent surgery for colorectal cancer. We also planned to determine how MSI affects prognostic parameters such as mortality rate, recurrence, disease-free survival, cancer-specific survival, and overall survival.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Colorectal surgery patients
  • Complete follow-up information

Exclusion criteria

  • Whose MSI status was not studied in the pathology material
  • Missing follow-up information
  • Colorectal resection for non-neoplastic diseases

Treatment and study plan

Microsatellite instability analysis

Diagnostic Test

Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.

Primary outcomes

  1. Overall Survival

    Time frame: Five years

    Overall survival is defined as the time interval from the time of primary operation to the date of all-cause death or the last follow-up.

  2. Disease-Free Survival

    Time frame: Five years

    Disease-Free Survival is defined as the time interval from the time of primary operation to disease recurrence or death.

Sponsors and collaborators

Lead sponsor

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

Other

Registry information

Official study title

Clinicopathological Outcomes of Microsatellite Instability in Colorectal Cancer

Acronym: MSI-CRC

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Dec 17, 2021
Registry last updated
Dec 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.